Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegaspargase - Servier

Drug Profile

Pegaspargase - Servier

Alternative Names: Asparaginase macrogol; Lyophilised pegaspargase - Servier; Oncaspar; PEG-asparaginase; PEG-L-asparaginase; PEGLA; S 95014; SHP674

Latest Information Update: 10 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Enzon Pharmaceuticals; Leadiant Biosciences; Medac; Servier; Shire
  • Class Amidohydrolases; Antineoplastics; Polyethylene glycols
  • Mechanism of Action Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Acute myeloid leukaemia

Most Recent Events

  • 23 Jan 2023 Servier completes a phase II trial in in pediatric patients with Acute lymphoblastic leukemia (ALL) in Russia (NCT04956666)
  • 20 May 2022 Servier completes a phase II trials for Precursor cell lymphoblastic leukaemia-lymphoma (In children, in infants, In adolescents) in Russia (IV) (NCT04954326)
  • 04 Feb 2022 Correct your HE - Servier completes a phase II trial in Precursor cell lymphoblastic leukaemia-lymphoma (Newly diagnosed, First-line therapy, In infants, In childrens, In adolescents, In adults) in Japan (IV) (NCT04067518)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top